Mutual of America Capital Management LLC Sells 758 Shares of Krystal Biotech, Inc. (NASDAQ:KRYS)

Mutual of America Capital Management LLC lessened its holdings in shares of Krystal Biotech, Inc. (NASDAQ:KRYS) by 2.0% during the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission. The firm owned 36,566 shares of the company’s stock after selling 758 shares during the quarter. Mutual of America Capital Management LLC owned about 0.13% of Krystal Biotech worth $6,656,000 at the end of the most recent quarter.

A number of other large investors also recently added to or reduced their stakes in the business. GAMMA Investing LLC lifted its holdings in shares of Krystal Biotech by 160.3% in the second quarter. GAMMA Investing LLC now owns 151 shares of the company’s stock worth $28,000 after buying an additional 93 shares in the last quarter. Jamison Private Wealth Management Inc. bought a new stake in Krystal Biotech in the 2nd quarter valued at $28,000. Key Financial Inc purchased a new stake in Krystal Biotech in the 2nd quarter worth $28,000. Blue Trust Inc. boosted its holdings in shares of Krystal Biotech by 2,328.6% during the 2nd quarter. Blue Trust Inc. now owns 170 shares of the company’s stock valued at $30,000 after purchasing an additional 163 shares during the last quarter. Finally, Values First Advisors Inc. purchased a new position in shares of Krystal Biotech during the third quarter valued at about $53,000. 86.29% of the stock is owned by hedge funds and other institutional investors.

Insiders Place Their Bets

In related news, insider Suma Krishnan sold 25,000 shares of Krystal Biotech stock in a transaction dated Thursday, September 12th. The stock was sold at an average price of $197.76, for a total value of $4,944,000.00. Following the completion of the sale, the insider now directly owns 1,500,882 shares in the company, valued at $296,814,424.32. The trade was a 1.64 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available through the SEC website. Company insiders own 14.10% of the company’s stock.

Krystal Biotech Trading Up 1.3 %

NASDAQ KRYS opened at $177.85 on Wednesday. The stock has a market cap of $5.11 billion, a PE ratio of 99.23 and a beta of 0.82. Krystal Biotech, Inc. has a 12 month low of $99.00 and a 12 month high of $219.34. The company’s 50-day moving average price is $180.59 and its 200-day moving average price is $181.90.

Krystal Biotech (NASDAQ:KRYS) last posted its quarterly earnings results on Monday, November 4th. The company reported $0.91 earnings per share for the quarter, beating the consensus estimate of $0.84 by $0.07. The firm had revenue of $83.84 million during the quarter, compared to the consensus estimate of $82.94 million. Krystal Biotech had a net margin of 21.68% and a return on equity of 7.54%. The company’s revenue was up 879.9% on a year-over-year basis. During the same quarter in the previous year, the firm posted ($0.67) earnings per share. As a group, sell-side analysts forecast that Krystal Biotech, Inc. will post 2.97 earnings per share for the current year.

Wall Street Analyst Weigh In

A number of research firms recently commented on KRYS. Citigroup boosted their target price on Krystal Biotech from $204.00 to $206.00 and gave the stock a “neutral” rating in a research report on Tuesday, November 5th. HC Wainwright restated a “buy” rating and set a $221.00 price objective on shares of Krystal Biotech in a research report on Tuesday, November 5th. Chardan Capital boosted their target price on Krystal Biotech from $153.00 to $208.00 and gave the company a “buy” rating in a research report on Monday, August 5th. Stifel Nicolaus raised their price target on Krystal Biotech from $204.00 to $220.00 and gave the stock a “buy” rating in a research report on Wednesday, September 11th. Finally, Cantor Fitzgerald reiterated an “overweight” rating on shares of Krystal Biotech in a research report on Thursday, August 29th. One equities research analyst has rated the stock with a hold rating, seven have given a buy rating and one has assigned a strong buy rating to the company. According to data from MarketBeat, the company has an average rating of “Buy” and a consensus price target of $197.00.

About Krystal Biotech

Krystal Biotech, Inc, a commercial-stage biotechnology company, discovers, develops, and commercializes genetic medicines for patients with rare diseases in the United States. It commercializes VYJUVEK (beremagene geperpavec-svdt, or B-VEC) for the treatment of dystrophic epidermolysis bullosa (DEB).